A new study has proposed that using Johnson & Johnson's Zytiga can help reduce size of prostate cancer in males. Zytiga was approved last year to treat prostate cancer in those men who had not shown any response to chemotherapies, they were subjected to. Moreover, the drug is stated to be given in combination with a steroid called prednisone.
During the course of study, researchers analyzed a group of men who were subjected to Zytiga, six months before surgery, after the six months time gap, it was noticed that in case of one-third of the men, the cancer was eliminated or reduced in size to a great extent.
After the successful achievement of the drug from the trial results, it has been discovered that the drug is now been studied further, so as to deploy it for use even during initial stages of the cancer.
However, it has been suggested that National Institute for Health and Clinical Excellence (NICE) takes too long for the approval of drugs, on an average, it has been estimated that NICE takes about five years from when a manufacturer obtains a license.
Rather, in a few cases, it has been reported that NICE begins its assessments after the treatment has been introduced in market.